Pembrolizumab: tested in a combination

521 studies: another drug in the study is under test too. Page 3 of 6. Open to participants first (187), then studies with results posted, then the rest; newest registration first within each.

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsTerminatedNCT04854434Phase 2Results posted Report a problem
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast CancerTerminatedNCT04849364Phase 2Results posted Report a problem
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate CancerActive, not recruitingNCT04848337Phase 2Results posted Report a problem
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04781088Phase 2Results posted Report a problem
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)CompletedNCT04776148Phase 3Results posted Report a problem
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaTerminatedNCT04768881Phase 2Results posted Report a problem
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.CompletedNCT04753879Phase 2Results posted Report a problem
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)CompletedNCT04704219Phase 2Results posted Report a problem
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint InhibitorsCompletedNCT04696055Phase 2Results posted Report a problem
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)CompletedNCT04662710Phase 3Results posted Report a problem
Trying to Find the Correct Length of Treatment With Immune Checkpoint TherapyActive, not recruitingNCT04637594Phase 3Results posted Report a problem
Pembrolizumab Plus Ramucirumab in Metastatic Gastric CancerCompletedNCT04632459Phase 2Results posted Report a problem
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04533451Phase 2Results posted Report a problem
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative ResectionTerminatedNCT04510285Phase 2Results posted Report a problem
Pembrolizumab and Olaparib in Cervical Cancer PatientsTerminatedNCT04483544Phase 2Results posted Report a problem
Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver CancerTerminatedNCT04442581Phase 2Results posted Report a problem
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)CompletedNCT04428151Phase 2Results posted Report a problem
Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer PatientsActive, not recruitingNCT04414540Phase 2Results posted Report a problem
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT04393350Phase 2Results posted Report a problem
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing SurgeryTerminatedNCT04370509Phase 2Results posted Report a problem
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaTerminatedNCT04322643Phase 2Results posted Report a problem
Study of Pembrolizumab and Olaparib in Bile Duct CancerCompletedNCT04306367Phase 2Results posted Report a problem
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)TerminatedNCT04267120Phase 2Results posted Report a problem
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Phase 3Results posted Report a problem
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT04223856Phase 3Results posted Report a problem
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric AdenocarcinomaCompletedNCT04209686Phase 2Results posted Report a problem
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal AdenocarcinomaCompletedNCT04164979Phase 2Results posted Report a problem
Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung CancerCompletedNCT04120454Phase 2Results posted Report a problem
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).CompletedNCT04068181Phase 2Results posted Report a problem
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal CancerActive, not recruitingNCT04030455Phase 2Results posted Report a problem
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)TerminatedNCT04003610Phase 2Results posted Report a problem
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149TerminatedNCT03997448Phase 2Results posted Report a problem
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck CancerCompletedNCT03993353Phase 2Results posted Report a problem
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder CancerActive, not recruitingNCT03978624Phase 2Results posted Report a problem
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)CompletedNCT03976375Phase 3Results posted Report a problem
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)CompletedNCT03971474Phase 2Results posted Report a problem
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.TerminatedNCT03968419Phase 2Results posted Report a problem
Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck CancerTerminatedNCT03938337Phase 2Results posted Report a problem
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)Active, not recruitingNCT03924895Phase 3Results posted Report a problem
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue SarcomasCompletedNCT03899805Phase 2Results posted Report a problem
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)CompletedNCT03884101Phase 3Results posted Report a problem
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)CompletedNCT03834519Phase 3Results posted Report a problem
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)CompletedNCT03797326Phase 2Results posted Report a problem
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)CompletedNCT03776136Phase 2Results posted Report a problem
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)CompletedNCT03740165Phase 3Results posted Report a problem
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)CompletedNCT03665597Phase 1Results posted Report a problem
Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's MacroglobulinaemiaCompletedNCT03630042Phase 2Results posted Report a problem
Lenvatinib and Pembrolizumab Simultaneous Combination StudyCompletedNCT03609359Phase 2Results posted Report a problem
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03559049Phase 1/2Results posted Report a problem
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial CarcinomaCompletedNCT03534804Phase 2Results posted Report a problem
The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC TrialCompletedNCT03523702Phase 2Results posted Report a problem
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation StatusCompletedNCT03519412Phase 2Results posted Report a problem
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])CompletedNCT03517449Phase 3Results posted Report a problem
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic LeukemiaTerminatedNCT03514017Phase 2Results posted Report a problem
Anti-PD-1 Antibody With HD IL-2 in Metastatic MelanomaTerminatedNCT03476174Phase 2Results posted Report a problem
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal CancerCompletedNCT03475004Phase 2Results posted Report a problem
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell CancerActive, not recruitingNCT03468218Phase 2Results posted Report a problem
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver MetastasesCompletedNCT03457948Phase 2Results posted Report a problem
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell LymphomaTerminatedNCT03401853Phase 2Results posted Report a problem
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)CompletedNCT03374254Phase 1Results posted Report a problem
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)CompletedNCT03358472Phase 3Results posted Report a problem
KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric CancerCompletedNCT03342937Phase 2Results posted Report a problem
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin LymphomaCompletedNCT03331341Phase 1/2Results posted Report a problem
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line TherapiesCompletedNCT03321630Phase 2Results posted Report a problem
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene MutationsCompletedNCT03299088Phase 1Results posted Report a problem
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine TumorsCompletedNCT03290079Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) in Combination With RomidepsinCompletedNCT03278782Phase 1/2Results posted Report a problem
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV MelanomaCompletedNCT03276832Early Phase 1Results posted Report a problem
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRCCompletedNCT03274804Phase 1Results posted Report a problem
Azacitidine and Pembrolizumab in Pancreatic CancerCompletedNCT03264404Phase 2Results posted Report a problem
Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial CancerCompletedNCT03240016Phase 2Results posted Report a problem
Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & TaxanesCompletedNCT03222856Phase 2Results posted Report a problem
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver CancerCompletedNCT03211416Phase 1/2Results posted Report a problem
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03204188Phase 2Results posted Report a problem
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced MelanomaCompletedNCT03200847Phase 1/2Results posted Report a problem
Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the LungCompletedNCT03157089Phase 2Results posted Report a problem
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in MelanomaActive, not recruitingNCT03149029Phase 2Results posted Report a problem
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast CancerCompletedNCT03121352Phase 2Results posted Report a problem
Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic SyndromeStatus unknownNCT03094637Phase 2Results posted Report a problem
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaCompletedNCT03082534Phase 2Results posted Report a problem
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingNCT03069378Phase 2Results posted Report a problem
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial SarcomaCompletedNCT03063632Phase 2Results posted Report a problem
Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for SarcomaCompletedNCT03056001Phase 2Results posted Report a problem
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine TumorsCompletedNCT03043664Phase 1/2Results posted Report a problem
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1CompletedNCT03032107Phase 1Results posted Report a problem
Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABCCompletedNCT03025880Phase 2Results posted Report a problem
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast CancerCompletedNCT03025035Phase 2Results posted Report a problem
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaCompletedNCT03006926Phase 1Results posted Report a problem
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT03006887Phase 1Results posted Report a problem
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast CancerCompletedNCT02999477Phase 1Results posted Report a problem
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT02996474Phase 1/2Results posted Report a problem
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-IntronTerminatedNCT02982720Phase 2Results posted Report a problem
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)CompletedNCT02973997Phase 2Results posted Report a problem
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaActive, not recruitingNCT02965716Phase 2Results posted Report a problem
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast CaActive, not recruitingNCT02957968Phase 2Results posted Report a problem
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal CancerCompletedNCT02921256Phase 2Results posted Report a problem
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)TerminatedNCT02906332Phase 2Results posted Report a problem
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal CancerCompletedNCT02865811Phase 2Results posted Report a problem
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III MelanomaActive, not recruitingNCT02858921Phase 2Results posted Report a problem
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)CompletedNCT02853331Phase 3Results posted Report a problem

← Pembrolizumab